Action Arch Biopartners - ARCH

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

1,72

Prix Achat

1,72

Prix Vente

1,87

Volume échangé

0,00 Fourchette du Jour 0,00

1,31 Plage de 52 semaines 2,56

Cap du marché

107,669M

Clôture Veille

1,72

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

16 155

Actions en circulation

62 598 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-32,02

Bénéfice par action (BPA)

-0,05

Chiffre d'affairess

1,98M

Bénéfice net

-3,33M

Secteur

Coml Physical, Biologcl Resh

Industrie

Advertising Agencies

Site Web

archbiopartners.com

Siège social

Toronto, Ontario, Can

Fondé

2010

Arch Biopartners Inc est coté dans le secteur Coml Physical, Biologcl Resh de la TSX Venture Exchange avec le ticker ARCH. Le dernier cours de clôture d'Arch Biopartners était de $1,72. Au cours de la dernière année, les actions de Arch Biopartners ont été négociées dans une fourchette de prix de $ 1,31 à $ 2,56.

Arch Biopartners compte actuellement 62 598 000 actions en circulation. La capitalisation boursière d'Arch Biopartners est de $107,67 million. Arch Biopartners a un ratio cours/bénéfice (ratio PE) de -32.02.

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.15	-8.02139037433	1.87	1.89	1.59	16096	1.75246602	CS
4	-0.24	-12.2448979592	1.96	2	1.59	14559	1.87848488	CS
12	-0.1	-5.49450549451	1.82	2.2	1.59	16155	1.94061513	CS
26	0.01	0.584795321637	1.71	2.2	1.36	15607	1.74782381	CS
52	0.24	16.2162162162	1.48	2.56	1.31	19520	1.82248399	CS
156	-2.16	-55.6701030928	3.88	4.25	0.97	20064	2.23536188	CS
260	0.74	75.5102040816	0.98	5.3	0.74	27043	1.99153259	CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?

The current share price of Arch Biopartners is $ 1,72

How many Arch Biopartners shares are in issue?

Arch Biopartners has 62 598 000 shares in issue

What is the market cap of Arch Biopartners?

The market capitalisation of Arch Biopartners is CAD 107,67M

What is the 1 year trading range for Arch Biopartners share price?

Arch Biopartners has traded in the range of $ 1,31 to $ 2,56 during the past year

What is the PE ratio of Arch Biopartners?

The price to earnings ratio of Arch Biopartners is -32,02

What is the cash to sales ratio of Arch Biopartners?

The cash to sales ratio of Arch Biopartners is 53,63

What is the reporting currency for Arch Biopartners?

Arch Biopartners reports financial results in CAD

What is the latest annual turnover for Arch Biopartners?

The latest annual turnover of Arch Biopartners is CAD 1,98M

What is the latest annual profit for Arch Biopartners?

The latest annual profit of Arch Biopartners is CAD -3,33M

What is the registered address of Arch Biopartners?

The registered address for Arch Biopartners is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1

What is the Arch Biopartners website address?

The website address for Arch Biopartners is archbiopartners.com

Which industry sector does Arch Biopartners operate in?

Arch Biopartners operates in the ADVERTISING AGENCIES sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,04 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,30 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,04 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,30 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0
AAAAAuralite Investments Inc	$ 0,265 (0,00%)	0
AAA.PFirst Tidal Acquisition Corp	$ 0,04 (0,00%)	0
AAAlba Minerals Ltd	$ 0,03 (0,00%)	0
A.HArmor Minerals Inc	$ 0,30 (0,00%)	0
AArmor Minerals Inc	$ 0,45 (0,00%)	0

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Arch Biopartners Inc (ARCH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Arch Biopartners Inc

ARCH Dernières nouvelles

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Arranges Non-Brokered Private Placement

Closes Units for Debt Settlement

Units for Debt Settlement

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

ARCH - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Arch Biopartners Inc (ARCH) Cours

Arch Biopartners Inc (ARCH)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Arch Biopartners Inc

ARCH Dernières nouvelles

ARCH - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application